Vanguard Portfolio Management’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$120M Sell
4,901,651
-19,608
-0.4% -$546K 0.01% 1412
2026
Q2
$169M Buy
4,921,259
+350,462
+8% +$10.6M 0.01% 1297
2026
Q1
$109M Buy
+4,570,797
New +$127M 0.01% 1416

Other funds holding BEAM

Vanguard Portfolio Management's BEAM Position: Q3 2026 in Review

Vanguard Portfolio Management reduced its Beam Therapeutics (BEAM) stake by 0.4% in Q3 2026, selling an estimated $546K and leaving 4,901,651 shares worth $120M. The position accounts for 0.01% of the portfolio, ranked #1412.

Vanguard Portfolio Management first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $169M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Vanguard Portfolio Management held 4,901,651 shares of Beam Therapeutics worth $120M as of Q3 2026.
  • Vanguard Portfolio Management sold 19,608 Beam Therapeutics shares in Q3 2026, an estimated $546K.
  • Beam Therapeutics made up 0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1412 holding.
  • Vanguard Portfolio Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Portfolio Management's Beam Therapeutics position peaked at $169M in Q2 2026.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.